Yes it's good to temper expectations a bit, only 65% of Americans have health insurance so the potential market is more like double the size of Japan not triple.
Also I recall a video of Matt or Howie saying that they think the insurance companies would likely only pay $540 so Bot will probably only charge $540 so there's no gap payment for consumers.
Another concern is the delay from the relabeling will have allowed people to try qbrexa and more than 40% of them will have experienced zero side effects so they are unlikely to change products if they are having success with the competition.
That said at $6000 per year per person 50,000 patients will bring in 300million $ so there is still amazing possibility for huge profits here. Aimo
Yes it's good to temper expectations a bit, only 65% of...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 34.0¢ | 32.0¢ | $1.776M | 5.339M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 118187 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 698385 | 8 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |